Skip to main content

FDA approvals

FDA Approves Relugolix for Advanced Prostate Cancer
FDA Alerts
12/18/2020
Journal of Clinical Pathways
FDA Approves Margetuximab for Metastatic Breast Cancer
FDA Alerts
12/17/2020
Journal of Clinical Pathways
News
12/01/2020
Journal of Clinical Pathways
FDA Approves Naxitamab for Neuroblastoma in Bone or Bone Marrow
FDA Alerts
11/28/2020
Journal of Clinical Pathways
News
07/01/2020
The Association of Community Cancer Centers (ACCC) Immuno-Oncology Institute released an assessment of the current state of immuno-oncology that highlights for cancer care professionals the current research,...
The Association of Community Cancer Centers (ACCC) Immuno-Oncology Institute released an assessment of the current state of immuno-oncology that highlights for cancer care professionals the current research,...
The...
07/01/2020
Journal of Clinical Pathways
Novel Ibrutinib Combination for Primary Treatment of CLL
Interview
06/22/2020
On April 21, 2020, the FDA expanded its approval of ibrutinib to include its use in combination with rituximab for the primary treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...
On April 21, 2020, the FDA expanded its approval of ibrutinib to include its use in combination with rituximab for the primary treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...
On...
06/22/2020
Journal of Clinical Pathways
Research in Review
12/05/2016
JCP Editors
The potential FDA approval of a new biosimilar to trastuzumab may help increase access to the treatment, which is recommended as first-line therapy for patients with ERBB2 (HER2)-positive breast...
The potential FDA approval of a new biosimilar to trastuzumab may help increase access to the treatment, which is recommended as first-line therapy for patients with ERBB2 (HER2)-positive breast...
The...
12/05/2016
Journal of Clinical Pathways
04/05/2016
JCP Editors
The National Comprehensive Cancer Network (NCCN) has announced three major changes to its guidelines for the treatment of multiple myeloma (MM) that broaden the population of patients eligible to start therapy,...
The National Comprehensive Cancer Network (NCCN) has announced three major changes to its guidelines for the treatment of multiple myeloma (MM) that broaden the population of patients eligible to start therapy,...
The...
04/05/2016
Journal of Clinical Pathways
04/04/2016
JCP Editors
Recent Food and Drug Administration (FDA) approvals have changed the landscape of treatment for chronic lymphocytic leukemia (CLL). In a session at the 2016 National Comprehensive Cancer Network (NCCN) Annual...
Recent Food and Drug Administration (FDA) approvals have changed the landscape of treatment for chronic lymphocytic leukemia (CLL). In a session at the 2016 National Comprehensive Cancer Network (NCCN) Annual...
Recent...
04/04/2016
Journal of Clinical Pathways